SpineThera Featured as a Minnesota Company Working On Alternatives for Opioid Pain Medication

Plymouth, Minnesota, United States, May 16, 2022 – SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of sciatica) announced today that biopharma executive Doug Drysdale and physician-scientist Dr. Shaheen Lakhan have joined SpineThera’s board of directors to support the further clinical development of SX600 and expansion of SpineThera’s product development pipeline.

Plymouth, Minnesota, United States, April 26, 2022 – SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that the Department of Defense has awarded the company a grant for $4.97 million that will support development of SX600. The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process development and scale-up activities. Together, these activities will position SX600 for future Phase 3 clinical trials.

Medical Alley, Minnesota, united states, March 9, 2022 – SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that Jeff Missling, Chief Executive Officer, will be presenting at the InCube meeting hosted by the West Virginia Society of Interventional Pain Physicians (WVSIPP) in Nashville, TN on March 13, 2022. InCube is being held in conjunction with the American Society of Pain and Neuroscience (ASPN) Think Tank meeting.